Literature DB >> 551086

[Pharmacokinetics of cefaclor and initial therapeutical experience (author's transl)].

H Lode, P Köppe, R Stahlmann.   

Abstract

Twelve normal volunteers in the fasting state were given 1000 mg cefaclor, and the serum and urine concentrations over 8 h and 24 h respectively were measured. The average peak serum concentration was 34.6 +/- 7.8 mg/l, this value being reached after 65.2 +/- 11.1 min; the half-life was 42.5 +/- 8.3 min. In another six volunteers the absorption of 500 mg of 'cefaclor following administration in the fasting state and after a test breakfast was studied. The peak serum concentrations after administration in the fasting state were 16.1 +/- 3.2 mg/l, and after a meal 12.5 +/- 1.9 mg/l; the areas under the curve did not differ. The low recovery rate of cefaclor in urine observed in this series of investigations could be partly explained by the inactivation of the substance in urine. Cefaclor was administered therapeutically to 23 patients, most of whom were suffering from bronchopulmonary infections and chronic pyelonephritis. The results of therapy were good in four patients, satisfactory in 13 patients and unsatisfactory in three patients. Intolerance was rare.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 551086     DOI: 10.1007/bf01659745

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  5 in total

1.  Stability and blood level determinations of cefaclor, a new oral cephalosporin antibiotic.

Authors:  M A Foglesong; J W Lamb; J V Dietz
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

2.  Kinetics of tissue penetration. Are high plasma peak concentrations or sustained levels preferable for effective antibiotic therapy?

Authors:  T Bergan
Journal:  Scand J Infect Dis Suppl       Date:  1978

3.  Penetration of antibiotics into fibrin loci in vivo. I. Comparison of penetration of ampicillin into fibrin clots, abscesses, and "interstitial fluid".

Authors:  M Barza; L Weinstein
Journal:  J Infect Dis       Date:  1974-01       Impact factor: 5.226

4.  An overview of the analysis and interpretation of bioavailability studies in man.

Authors:  J G Wagner
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

5.  [Comparative clinical pharmacology of gentamicin, sisomicin, and tobramycin].

Authors:  H Lode; B Kemmerich; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1975-10       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.